The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars.

The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.

The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars.